Humoral Response of Patients With Autoimmune Rheumatic Disease to BNT162b2 Vaccine: A Retrospective Comparative Study.
anti-sars-cov-2 vaccine
autoimmune rheumatic disease
disease modifying antirheumatic drug
humoral immune response
rituximab
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
accepted:
29
04
2022
entrez:
2
6
2022
pubmed:
3
6
2022
medline:
3
6
2022
Statut:
epublish
Résumé
Objective The effectiveness and safety of SARS-CoV-2 vaccines in patients with autoimmune rheumatic diseases (ARDs) treated with immunomodulators remain uncertain. Therefore, this study aimed to evaluate whether the humoral immune response to the BNT162b2 vaccine differs between patients without and with ARDs treated with immunomodulators. Methods We retrospectively reviewed 3208 electronic medical records from the database of the Hamad Medical Corporation (HMC) outpatient rheumatology clinics to capture patients with ARDs and control patients without autoimmune inflammatory diseases. All patients who were SARS-CoV-2 infection-naïve, had received two doses of BNT162b2 vaccination, and had been serologically tested using Elecsys® anti-SARS-CoV-2 S immunoassays (Roche Holdings AG, Basel, Switzerland), were included in the analysis. Patients with ARD were classified into six subgroups according to the received ARD immunomodulators: methotrexate monotherapy (MTXM), a combination of conventional synthetic disease-modifying antirheumatic drugs (Cs-DMARDs), tumor necrosis factor inhibitor (TNF-i), rituximab, interleukin-6 inhibitor (IL6-i), and Janus kinase inhibitor (JAK-i). Samples with an anti-SARS-CoV-2 S titer of <0.8 and <132 binding antibody unit (BAU)/mL were defined as negative and poor seroconversion, respectively. The overall mean of anti-SARS-CoV-2 S titer and its level at <0.8 and <132 were compared between the six subgroups of patients with ARD and the controls by performing an unpaired
Identifiants
pubmed: 35651432
doi: 10.7759/cureus.24585
pmc: PMC9138718
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e24585Informations de copyright
Copyright © 2022, Alsaed et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Heart Lung Transplant. 2021 Aug;40(8):759-762
pubmed: 34034958
Arthritis Care Res (Hoboken). 2014 Jul;66(7):1016-26
pubmed: 24339395
Lancet Rheumatol. 2021 Nov;3(11):e778-e788
pubmed: 34396154
Ann Rheum Dis. 2011 Dec;70(12):2144-7
pubmed: 21859696
Ann Rheum Dis. 2021 Oct;80(10):1345-1350
pubmed: 34285048
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Ann Intern Med. 2021 Sep;174(9):1336-1338
pubmed: 34029487
Ann Rheum Dis. 2021 Oct;80(10):e158
pubmed: 34049854
Am J Transplant. 2021 Aug;21(8):2719-2726
pubmed: 33866672
Ann Rheum Dis. 2021 Oct;80(10):1306-1311
pubmed: 33762264
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Arthritis Rheum. 2011 Dec;63(12):3723-32
pubmed: 21834061
Ann Rheum Dis. 2021 Oct;80(10):1339-1344
pubmed: 34035003
Ann Rheum Dis. 2021 Oct;80(10):1330-1338
pubmed: 34127481
Ann Rheum Dis. 2017 Sep;76(9):1559-1565
pubmed: 28468794
Am J Transplant. 2021 Aug;21(8):2913-2915
pubmed: 33864722
Rheumatology (Oxford). 2006 Jan;45(1):106-11
pubmed: 16287919